Clinical trial · no report yet · Phase 3
eVOLVE-Lung02
A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung Cancer.
- NCT05984277 ↗
- Active not recruiting
- AstraZeneca
- 3 commentary sources found
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built. Commentary is thin so far, so the report would be short.
| Channel | Found | |
|---|---|---|
| X threads | 3 |
The trial
ClinicalTrials.gov- Official title
- A Phase III, Two-Arm, Parallel, Randomized, Multi-Center, Open-Label, Global Study to Determine the Efficacy of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for First-Line Treatment of Patients With Metastatic Non-Small Cell Lung Cancer (mNSCLC).
- Phase
- Phase 3
- Status
- Active not recruiting
- Conditions
- Metastatic Non-small Cell Lung Cancer
- Interventions
- Volrustomig; Pembrolizumab; Carboplatin; Paclitaxel; Pemetrexed
- Arms
- Arm 1 · Experimental
- Arm 2 · Active comparator
- Enrollment
- 895
- Primary outcomes
- Progression-Free Survival (PFS) (using BICR assessments according to RECIST 1.1)
- Overall Survival (OS), in PD-L1-negative participants.
- Sponsor
- AstraZeneca
- Start
- Oct 24, 2023
- Primary completion
- Aug 17, 2026
- Results posted
- No
- Registry record
- NCT05984277 · updated Oct 9, 2026